Limitations of the active‑site paradigm and bottleneck of undruggable target protein loss Traditional small‑molecule inhibitors that have dominated the conventional medicinal chemistry pipeline function by physically docking into a specific active site of disease‑causing proteins, thereby occupying and blocking their function. However, more than 80 % of disease‑associated proteins encoded by the human genome lack such drug‑binding pockets due to their structural characteristics, leading to an “undruggable” classification and leaving them in a clinical blind spot. A one‑dimensional strategy that merely blocks the active site is vulnerable to the protein’s structural robustness and resistance‑variant spike noise, creating a critical technical bottleneck for achieving a reversible therapeutic golden window in refractory cancers and neurodegenerative diseases.

Activation of bifunctional heterobifunctional molecules (PROTAC): Demonstration of ternary‑complex formation and ubiquitin catalytic turnover In the study published in Nature Biotechnology on June 4, the authors deployed a PROTAC (Proteolysis Targeting Chimera) platform to fundamentally neutralize the binding‑pocket barrier by simultaneously binding the protein of interest (POI) and an E3 ubiquitin ligase at opposite ends, thereby enforcing productive proximity. The team modeled linker length and physicochemical entropy tensors in silico to optimize the kinetics of ternary‑complex formation between the two large proteins. Consequently, they achieved robust polyubiquitination of the target protein surface and demonstrated intact catalytic turnover that directs the substrate to the intracellular 26S proteasome for irreversible degradation.

First FDA approval of a targeted protein degrader: Molecular‑biological validation of the therapeutic destruction hypothesis A drug pipeline derived from the identified PROTAC platform backbone achieved the historic first FDA approval. The significance of this clearance extends beyond superior performance relative to existing anticancer agents; it formally validates that the mechanism of forcibly degrading any intracellular protein to eliminate disease‑causing factors can operate safely and effectively in humans. This enables a patient‑stratification model that eliminates false‑positive prognostic noise and preserves the integrity of precision “pin‑clamp” targeting of previously abandoned oncogenic driver proteins lacking druggable sites.

Standardization of programmable TPD supply chain and a shift in global pharmaceutical governance paradigm This integrated chemogenomics and molecular pharmacology data white paper resets global drug‑R&D governance from a simple protein‑function inhibition model to a programmable protein‑elimination infrastructure that computationally filters electrostatic interface tensors between ligase and target to eradicate disease drivers. Multinational pharmaceutical companies now compute the binding free energy of linker libraries during premium drug‑development stages, establishing a computational moat that pre‑calculates CMC (Chemistry, Manufacturing, and Controls) viability thresholds. The defined PROTAC receptor dissociation constants will serve as master assets that satisfy the quantitative frameworks for digital‑health companion‑diagnostic (CDx) platforms and next‑generation targeted protein degrader pipelines in global IND submissions.